Bank of New York Mellon Corp Has $26.93 Million Stake in Twist Bioscience Co. (NASDAQ:TWST)

Bank of New York Mellon Corp lessened its holdings in Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 5.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 579,576 shares of the company's stock after selling 35,373 shares during the quarter. Bank of New York Mellon Corp owned 0.98% of Twist Bioscience worth $26,933,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in TWST. Massachusetts Financial Services Co. MA boosted its stake in shares of Twist Bioscience by 215.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company's stock worth $1,324,000 after buying an additional 20,035 shares during the last quarter. Barclays PLC grew its stake in Twist Bioscience by 214.8% in the third quarter. Barclays PLC now owns 153,039 shares of the company's stock valued at $6,913,000 after purchasing an additional 104,420 shares in the last quarter. FMR LLC increased its position in shares of Twist Bioscience by 6.0% during the 3rd quarter. FMR LLC now owns 218,561 shares of the company's stock worth $9,875,000 after purchasing an additional 12,327 shares during the last quarter. Avanza Fonder AB bought a new stake in shares of Twist Bioscience during the 4th quarter worth approximately $1,059,000. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Twist Bioscience by 128.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company's stock valued at $1,718,000 after buying an additional 21,357 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on TWST shares. Barclays set a $58.00 price target on shares of Twist Bioscience and gave the stock an "overweight" rating in a research report on Monday, February 3rd. Robert W. Baird raised their target price on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a research note on Tuesday, February 4th. TD Cowen reissued a "buy" rating and set a $58.00 price target on shares of Twist Bioscience in a research report on Tuesday, November 26th. Wolfe Research began coverage on Twist Bioscience in a research report on Friday, December 13th. They issued an "outperform" rating and a $60.00 price objective for the company. Finally, Scotiabank restated an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, Twist Bioscience presently has an average rating of "Moderate Buy" and an average price target of $54.40.

Remove Ads

Twist Bioscience Stock Performance

TWST stock traded up $0.28 during trading hours on Wednesday, hitting $39.41. 780,571 shares of the stock were exchanged, compared to its average volume of 997,161. Twist Bioscience Co. has a 12 month low of $27.41 and a 12 month high of $60.90. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $2.35 billion, a P/E ratio of -11.66 and a beta of 2.15. The company has a 50-day simple moving average of $46.18 and a two-hundred day simple moving average of $45.39.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, topping analysts' consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The business had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. During the same period last year, the firm earned ($0.75) earnings per share. Twist Bioscience's revenue for the quarter was up 24.1% compared to the same quarter last year. On average, analysts forecast that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Insider Buying and Selling at Twist Bioscience

In other news, CEO Emily M. Leproust sold 1,654 shares of the business's stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $44.90, for a total value of $74,264.60. Following the completion of the transaction, the chief executive officer now directly owns 673,064 shares in the company, valued at approximately $30,220,573.60. The trade was a 0.25 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Adam Laponis sold 5,886 shares of Twist Bioscience stock in a transaction on Friday, January 10th. The shares were sold at an average price of $43.26, for a total value of $254,628.36. Following the completion of the transaction, the chief financial officer now owns 110,096 shares in the company, valued at approximately $4,762,752.96. The trade was a 5.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 33,845 shares of company stock valued at $1,603,945 in the last three months. Corporate insiders own 3.01% of the company's stock.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.